ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 90 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2020. The put-call ratio across all filers is 0.71 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,510 | -95.3% | 523 | -92.7% | 0.00% | – |
| Q2 2023 | $53,614 | +1182.3% | 7,139 | +671.8% | 0.00% | – |
| Q1 2023 | $4,181 | -66.7% | 925 | -17.0% | 0.00% | – |
| Q4 2022 | $12,555 | +4.6% | 1,114 | -11.3% | 0.00% | – |
| Q3 2022 | $12,000 | -42.9% | 1,256 | -51.5% | 0.00% | – |
| Q2 2022 | $21,000 | -95.1% | 2,592 | -89.7% | 0.00% | – |
| Q1 2022 | $426,000 | -77.1% | 25,183 | -70.9% | 0.00% | -100.0% |
| Q4 2021 | $1,863,000 | +7.9% | 86,677 | +271.0% | 0.00% | 0.0% |
| Q3 2021 | $1,726,000 | -54.6% | 23,366 | -66.4% | 0.00% | -50.0% |
| Q2 2021 | $3,799,000 | -5.8% | 69,469 | +27.0% | 0.00% | -33.3% |
| Q1 2021 | $4,033,000 | +1366.5% | 54,690 | +1613.9% | 0.00% | – |
| Q4 2020 | $275,000 | +99.3% | 3,191 | -12.7% | 0.00% | – |
| Q3 2020 | $138,000 | – | 3,654 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |